Omeros Scores its First FDA Nod as Stem Cell Transplant Drug Yartemlea Approved

Omeros has secured its first FDA approval with the authorization of narsoplimab, now marketed as Yartemlea. The drug is the first treatment approved for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in patients aged 2 and older, representing a significant milestone for the Seattle-based biotech.